Navigation Links
InterMune to Present at Bank of America Health Care Conference
Date:5/9/2008

BRISBANE, Calif., May 9 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Dan Welch, President and Chief Executive Officer of InterMune, will present at the Bank of America 2008 Health Care Conference in Las Vegas on May 14, 2008 at 9:20 a.m. PDT (12:20 p.m EDT).

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at http://www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
11. Avicena Group to Present at Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... (PRWEB) August 21, 2014 Pursuit ... selling optimization technology and services for Life Sciences ... “Grading Pharma’s Use of New Commercial Sales Models” ... & Analytics. , The article examines some innovative ... that are being tested in the pharmaceutical market. ...
(Date:8/21/2014)... Louis, MO (PRWEB) August 21, 2014 ... full service biopharmaceutical contract development and manufacturing organization ... by Progenics Pharmaceuticals, Inc., an oncology company focused ... and treating cancer, to manufacture the anti-prostate specific ... PSMA ADC product candidate. Under the agreement ...
(Date:8/21/2014)... On Wednesday of last week RENU 28, ... Signaling molecules, became available for purchase in Australia and New ... that RENU 28 works is, if you think about the ... rate of cellular renewal within your body. If you think ... rate of cellular renewal. What RENU 28 does is it ...
(Date:8/20/2014)... An analysis of patented university inventions licensed to ... path to commercialization. To open these roadblocks, the ... results during the discovery stage could lead to ... are frequently derived from discoveries made in university ... well known during clinical trials, which have a ...
Breaking Biology Technology:Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3RENU 28 Skin Care Now Available in Australia and New Zealand 2Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3
... DRRX ) announced today that a New ... submitted to the U.S. Food,and Drug Administration (FDA). ... formulation of oxycodone intended to treat moderate to ... designed to resist,common methods of prescription drug misuse ...
... to advance Merrimack,s robust pipeline of biologics ... targeting autoimmune disease and cancer, CAMBRIDGE, Mass., ... the discovery and development of,novel treatments for autoimmune disease and ... Series F private equity financing., Existing and new investors ...
... Bioheart, Inc.,(Nasdaq: BHRT ) today announced that ... common stock to the Nasdaq Capital Market. The Company,s,common ... to The,Nasdaq Capital Market at the opening of business ... a tier of the Nasdaq Stock Market for,companies with ...
Cached Biology Technology:New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 2New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 3New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 4New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 5Merrimack Pharmaceuticals Raises $60 Million in Private Financing 2Bioheart, Inc. to Transfer to Nasdaq Capital Market 2
(Date:8/21/2014)... -- Nxt-ID, Inc. (OTCQB: NXTD), a biometric authentication company ... that its shares of common stock and the warrants ... proposed underwritten public offering of common stock and warrants ... Market, subject to closing of its proposed underwritten public ... trade under the symbol "NXTD" and "NXTDW," respectively. ...
(Date:8/21/2014)... aimed at improving the food intake, health and quality ... is among three projects at the University of Waterloo ... Canadian Institutes of Health Research (CIHR). , Professor ... at Waterloo, and a Schlegel research chair in nutrition ... investigate why many Canadians living in long-term care homes ...
(Date:8/21/2014)... Wednesday, Oct. 18-22, 2014 , WHERE: , ... San Diego, CA 92101 , WHAT: , ... of the latest research in human genetics. Examples ... high-scoring abstracts on rare genetic variants in health ... treatment for sun sensitivity (Saturday, Oct. 18, 5:30-7:30 ...
Breaking Biology News(10 mins):Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3Grants will fund landmark aging research at Waterloo 2American Society of Human Genetics 2014 Annual Meeting 2
... (UW) have reported for the first time that mammals can ... retinas. Located in the back of the eye, the retina,s ... to the brain. The findings on retina self-repair in ... of the Proceedings of the National Academy of Sciences ...
... Institute of Technology has invited a longtime University of ... and presenting seminars on its campus. Fazle Hussain, ... Engineering, was the sole recipient of the Gordon and ... for Caltech,s division of engineering and applied sciences. The ...
... University have answered a fundamental question of how important ... function, a finding that could provide a new target ... diseases. In a study published this month in ... show for the first time that the specific movements ...
Cached Biology News:Mammals can be stimulated to regrow damaged inner retina nerve cells 2Mammals can be stimulated to regrow damaged inner retina nerve cells 3Celebrated UH researcher invited to Caltech as distinguished scholar 2Scientists present 'moving' theory behind bacterial decision-making 2
Human Cystatin F MAb (Clone 292103)...
... Ac-DEVD-CHO is an inhibitor ... The concentration of inhibitor ... activity must be determined ... Ten micromolar inhibitor is ...
Human RELT/TNFRSF19L Affinity Purified Polyclonal Ab...
Mouse NOV/CCN3 Affinity Purified Polyclonal Ab...
Biology Products: